Mrl Ventures Fund

BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris

Plus: Hwang joins Metaphore, Flagship and updates from FDA, MHRA, ArrePath, ABT, Unnatural, Thryv and more

Plus: Launches for Sofinnova-backed AI company Bioptimus, peptide start-up Insamo

Plus: Nouscom raises €67.5M series C and more from Eyebio, Glox, Bayer and Ketabon

Plus: EQT, Forbion lead €129M A round for VectorY and updates from ViaNautis Bio, Cartesian, Aclaris, Anthos, Basilea, and Blueberry 

With $100M in series A funding, ‘2.0’ gene therapy company aims to treat retinitis pigmentosa using a channelrhodopsin variant designed for greater light sensitivity

Plus: Zura raises $80M, adds bifunctional asset in Lilly deal and updates from Foresite Diagnostics, Adcentrx, Pattern, Antiva and Mezzion

After evaluating options, Sesen chooses Carisma option among dozens of bids, creating third incarnation of public company

Scientific founder Amit Choudhary launched the newco with Longwood Fund; MPM led the A round

Plus Takeda’s dengue vaccine gets first global approval, and updates from Pfizer, AstriVax, Ordaos, Zelluna and more